Shares of Hims & Hers Health Inc. (HIMS) gained in Thursday\u2019s opening trade after the company announced that it is expanding its lineup of GLP-1 treatments on the platform to include offerings from Eli Lilly & Co. (LLY).<\/p>\n
Hims & Hers stated that Lilly\u2019s Zepbound, Mounjaro, and Foundayo are now available to providers on the platform, allowing them to offer self-pay pricing for these treatments to their customers.<\/p>\n
This comes a month after the company\u00a0launched<\/a> a waitlist for Novo Nordisk AS\u2019s (NVO) Ozempic and Wegovy.<\/p>\n Hims & Hers shares<\/a> were up nearly 4% in Thursday\u2019s opening trade.<\/p>\n CEO Compares It To Netflix\u2019s Early Days<\/p>\n Hims & Hers CEO Andrew Dudum compared the development with Netflix Inc.\u2019s (NFLX) early days.<\/p>\n \u201cIn many ways, today reminds me of Netflix\u2019s early days, when everyone talked about whether they would have the latest blockbuster in their catalog. As if Netflix\u2019s success depended on its ability to become the distribution channel for a single film,\u201d Dudum\u00a0said<\/a> in a post on X.<\/p>\n He added that people missed the forest for the trees, noting that Netflix was prioritizing choice and inventing new pathways to what people wanted most.<\/p>\n \u201cBy offering a full range of FDA-approved GLP-1s on our platform, we\u2019re similarly giving our customers more choices through all the tools we have available \u2013 and we\u2019ll continue to push here on behalf of everyone who depends on us for their care,\u201d he said.<\/p>\n What Are The Weight Loss Options On Hims & Hers?<\/p>\n Hims & Hers currently offers a range of FDA-approved GLP-1 treatments on its platform.<\/p>\n This includes Zepbound, Zepbound Vial, and Zepbound KwikPen, with prices starting at $199 per month. The telehealth platform also offers the Foundayo pill at $149 per month and Mounjaro at $1,899 per month.<\/p>\n Customers can also opt for Novo Nordisk\u2019s offerings, such as Ozempic and Wegovy, in pill or pen form, with prices starting at $149 per month.<\/p>\n Access to these medications requires an active membership, available for $39 for the first month and $149 thereafter.<\/p>\n The company previously stated that it would educate U.S. weight-loss customers about their options across a broader range of FDA-approved treatments. When providers determine it is clinically appropriate, Hims & Hers will help support a smooth transition to these medications, it said.<\/p>\n How Did Retail Traders React?<\/p>\n Retail sentiment on Stocktwits around\u00a0Hims & Hers<\/a> trended in the \u2018extremely bullish\u2019 territory with message volumes at \u2018extremely high\u2019 levels at the time of writing.<\/p>\n One bullish user stated that the HIMS stock could see a run-up before the next earnings report.<\/p>\n Another user referenced Dudum\u2019s comparison with Netflix, saying that exciting times are ahead.<\/p>\n HIMS stock<\/a> is down 8% year-to-date, but up 12% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 33% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF Shares (VB) is up 35%.<\/p>\n NVO stock<\/a> is down 24% YTD, while\u00a0LLY stock<\/a> is down 14%.<\/p>\n Also See:\u00a0TXN Stock Extends Gains To 6th Consecutive Week \u2014 Why Are Analysts Bullish?<\/strong><\/a><\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n
![\"Follow](\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/){kind=icon}
<\/a><\/p>\n